TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

SPAC Merger To Take SL Bio Public Through New Entity In 2026

Benzinga Logo Benzinga By Priya Nigam
SPAC Merger To Take SL Bio Public Through New Entity In 2026

Taiwan-based biotechnology firm SL Bio Ltd. has filed a Form F-4 to merge with Horizon Space Acquisition II Corp. (NASDAQ:HSPT), taking the company public via SPAC at an implied equity valuation of $5.7 billion. The combined entity will operate as SL Science Holding Limited under ticker SLBT, with the public listing expected in early 2026. SL Bio focuses on cellular and gene therapy technologies, immunotherapies for oncology, and exosome-based regenerative technologies.

Insights
WMT   positive

Supporting sustainable practices and supply chain optimization


HSPT   neutral

As the SPAC acquisition vehicle, HSPT shareholders will benefit from exposure to SL Bio's operations, but the sentiment is neutral as SPACs are primarily vehicles for the transaction rather than operating entities with independent business performance.